Seehra Jasbir 4
4 · Keros Therapeutics, Inc. · Filed Apr 13, 2020
Insider Transaction Report
Form 4
Seehra Jasbir
DirectorCHIEF EXECUTIVE OFFICER
Transactions
- Conversion
Series C Preferred Stock
2020-04-13−11,169→ 0 total→ Common Stock (11,169 underlying) - Conversion
Common Stock
2020-04-13+11,169→ 223,856 total - Purchase
Common Stock
2020-04-13$16.00/sh+20,000$320,000→ 243,856 total
Footnotes (1)
- [F1]Each share of Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date.